ReviewThe Journal of general virology2015
Recent vaccine development for human metapneumovirus.
Review in The Journal of general virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 49 citations in OpenAlex.
- Cardio-Renal Diseases Are Independent Risk Factors of Severe Human Metapneumovirus Infection Among Patients Without Chronic Airway Diseases.Journal of medical virology · 2026Article
- Development of a multi-epitope vaccine candidate targeting conserved regions of human metapneumovirus.Virusdisease · 2025Article
- Human Metapneumovirus and Respiratory Syncytial Virus in Children: A Comparative Analysis.Pediatrics · 2025Article
- Human Metapneumovirus: A Narrative Review on Emerging Strategies for Prevention and Treatment.Viruses · 2025Review
- Human Metapneumovirus: A Comprehensive Epidemiological Analysis of a Global Respiratory Threat.Infection & chemotherapy · 2025Review
- Review
- Design and validation of a semi-quantitative microneutralization assay for human Metapneumovirus A1 and B1 subtypes.Scientific reports · 2025Article
- Minireview: Designing next generation human metapneumovirus (HMPV) vaccine.Clinical and experimental vaccine research · 2025Review
- The surge of human metapneumovirus (hMPV) cases in China and global implications.New microbes and new infections · 2025Article
- Epidemiology of human metapneumovirus in Taiwan from 2013 to 2023.Archives of virology · 2024Article
- Article
- Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy Adults.Open forum infectious diseases · 2022Article
- A chimeric influenza virus vaccine expressing fusion protein epitopes induces protection from human metapneumovirus challenge in mice.Frontiers in microbiology · 2022Article
- Bacterial and Viral Coinfections with the Human Respiratory Syncytial Virus.Microorganisms · 2021Review
- Viral etiology and epidemiology of pediatric patients hospitalized for acute respiratory tract infections in Macao: a retrospective study from 2014 to 2017.BMC infectious diseases · 2021Article
- Lower respiratory tract infection in the community: associations between viral aetiology and illness course.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2021Article
- Editorial: From Pathogenic Infections to Inflammation and Disease - the Tumultuous Road of the 'Cytokine Storm'.Frontiers in cellular and infection microbiology · 2021Article
- Engineering of Live Chimeric Vaccines against Human Metapneumovirus.Pathogens (Basel, Switzerland) · 2020Review
- Post-pandemic influenza A/H1N1pdm09 is associated with more severe outcomes than A/H3N2 and other respiratory viruses in adult hospitalisations.Epidemiology and infection · 2019Article
- Epidemiological, clinical and genotypic features of human Metapneumovirus in patients with influenza-like illness in Senegal, 2012 to 2016.BMC infectious diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Human metapneumovirus (hMPV) and respiratory syncytial virus, its close family member, are two major causes of lower respiratory tract infection in the paediatric population. hMPV is also a common cause of worldwide morbidity and mortality in immunocompromised patients and older adults. Repeated infections occur often, demonstrating a heavy medical burden. However, there is currently no hMPV-specific prevention treatment. This review focuses on the current literature on hMPV vaccine development. We believe that a better understanding of the role(s) of viral proteins in host responses might lead to efficient prophylactic vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.